Adequate information about infant nutrition Appropriate marketing and distribution of breast milk substitutes. The MAIF Agreement is of implementing the World Health Australia’s primary means International Code of Marketing Breast-milk Substitutes (WHO Code). The MAIF Organization’s Agreement implements those aspects of the WHO Code that are appropriate to legal Australia’s and economic environment. Australian manufacturers and importers who are parties to the MAIF Agreement undertake to observe its provisions with respect to marketing and promotion of formulas for infants up to 12 months of age. The MAIF Agreement applies to: Infant formula, i.e., formula that is suitable for babies from birth (often described as Starter, Stage 1 or All Ages infant formulas) Follow-on formulas, i.e., formula that is suitable for babies aged six to twelve months. The MAIF Agreement does not apply to: Toddler milk drinks (sometimes called Growing Up milks) Complementary foods (such as baby cereal and packaged baby foods) Feeding bottles and teats The Tribunal has no formal powers to obtain information about a complaint. The Tribunal relies for information on voluntary cooperation from the parties to the MAIF Agreement and on other stakeholders. Current signatories to the MAIF Agreement include (as at 30 June 2016): A2 Corporation Ltd Abbott Australasia Pty Ltd Aspen Nutritionals Australia Pty Ltd Australian Dairy Park Pty Ltd Bayer Australia Ltd Devondale Murray Goulburn H J Heinz Company Australia Ltd Nature One Dairy Pty Ltd Nestlé Australia Ltd Nutricia Australia Pty Ltd Authorisation of MAIF Agreement The MAIF Agreement was authorised by the then Trade Practices Commission on 23 September 1992. Authorisation of the MAIF Agreement was necessary because it contains marketing restrictions limiting competition and was granted on the basis that public benefit outweighed any anti-competitive detriment. Authorised organisations can legally follow the provisions of the MAIF Agreement, but could be in breach of the Trade Practices Act 1974 if they agree to any further marketing restriction which is not covered in the MAIF Agreement, even if it is recommended in the WHO Code.
Adequate information about infant nutrition Appropriate marketing and distribution of breast milk substitutes. The MAIF Agreement is Australia’s primary means of implementing the World Health Organization’s International Code of Marketing Breast-milk Substitutes (WHO Code). The MAIF Agreement implements those aspects of the WHO Code that are appropriate to Australia’s legal and economic environment. Australian manufacturers and importers who are parties to the MAIF Agreement undertake to observe its provisions with respect to marketing and promotion of formulas for infants up to 12 months of age. The MAIF Agreement applies to: Infant formula, i.e., formula that is suitable for babies from birth (often described as Starter, Stage 1 or All Ages infant formulas) Follow-on formulas, i.e., formula that is suitable for babies aged six to twelve months. The MAIF Agreement does not apply to: Toddler milk drinks (sometimes called Growing Up milks) Complementary foods (such as baby cereal and packaged baby foods) Feeding bottles and teats The Tribunal has no formal powers to obtain information about a complaint. The Tribunal relies for information on voluntary cooperation from the parties to the MAIF Agreement and on other stakeholders. Current signatories to the MAIF Agreement include (as at 30 June 2016): A2 Corporation Ltd Abbott Australasia Pty Ltd Aspen Nutritionals Australia Pty Ltd Australian Dairy Park Pty Ltd Bayer Australia Ltd Devondale Murray Goulburn H J Heinz Company Australia Ltd Nature One Dairy Pty Ltd Nestlé Australia Ltd Nutricia Australia Pty Ltd Authorisation of MAIF Agreement The MAIF Agreement was authorised by the then Trade Practices Commission on 23 September 1992. Authorisation of the MAIF Agreement was necessary because it contains marketing restrictions limiting competition and was granted on the basis that public benefit outweighed any anti-competitive detriment. Authorised organisations can legally follow the provisions of the MAIF Agreement, but could be in breach of the Trade Practices Act 1974 if they agree to any further marketing restriction which is not covered in the MAIF Agreement, even if it is recommended in the WHO Code.